BCR and pachyonychia congenita: However, the majority of these studies focus on weak surrogates of cancer-specific survival (CSS) (e.g., BCR which is an early and easily measured endpoint) [11] and a recent meta-analysis validated the MFS as a more meaningful clinical endpoint and the only identified surrogate endpoint for overall survival (OS) in localized PC [12].